30 July 2026
Oncostellae to Participate in the 26th Annual Biotech in Europe Forum in Basel organized by Sachs Associates

julio 30, 2026

---

Santiago de Compostela, Spain – 30 July 2026 – Oncostellae, a clinical-stage biotechnology company developing innovative therapies for immune-mediated diseases, today…

Read More

22 January 2026
Development of OST-499:
Asabys-backed Oriva Therapeutics launches to advance novel treatments for women’s health

enero 22, 2026

---

Oriva Therapeutics is launched with the support of Asabys, focused on developing innovative therapies in women’s health The company incorporates two…

Read More

5 September 2025
Oncostellae Strengthens Business Development Activities at BIO-Europe 2025 in Vienna

septiembre 5, 2025

---

Santiago de Compostela, Spain – 5 September 2025 – Oncostellae, a clinical-stage biopharmaceutical company developing innovative therapies for inflammatory and immune-mediated…

Read More

February 2025
Oncostellae Receives European Commission Seal of Excellence for OST-122 IBD Project

febrero 1, 2025

---

Santiago de Compostela, February 2025 – Oncostellae S.L., a clinical-stage biopharmaceutical company developing innovative therapies for immune-mediated and other diseases, announced…

Read More

6 July 2023
Bio&Tech Smart Capital injects €500,000 into Oncostellae and joins the board

julio 6, 2023

---

Santiago-headquartered biopharmaceutical company Oncostellae has just wrapped up a funding round raising €3.3 million to complete Phase 2 clinical trials of…

Read More

15 December 2022
A biopharmaceutical company from A Coruña is developing a pioneering drug for ulcerative colitis

diciembre 15, 2022

---

A Coruña-based biopharmaceutical company Oncostellae is developing a new drug to treat ulcerative colitis, targeting patients with moderate to severe symptoms…

Read More

4 July 2022
The Galician government supports the biotechnology company Oncostellae to advance clinical trials with new pharmaceutical compounds

julio 4, 2022

---

Santiago de Compostela, 4 July 2022. XesGalicia, an investment body dependent on the Xunta de Galicia, will participate through its Galicia…

Read More

25-28 Oct 2021
Oncostellae intensifies partnering process at BIO-Europe to outlicense OST-122, a safe and non-systemic JAK3/TYK2/ARK5 inhibitor for IBD

septiembre 30, 2021

---

Oncostellae participates at the BIO-Europe partnering event taking place on October 25-28, 2021 in a digital format. The company is in…

Read More